Trials / Conditions / Age Related Macular Degeneration (ARMD)

Age Related Macular Degeneration (ARMD)

13 registered clinical trials studyying Age Related Macular Degeneration (ARMD) — 6 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	A Phase 1 Study of ABF-101 in Single- and Multiple-Ascending Doses NCT07330674	Aptabio Therapeutics, Inc.	Phase 1
Not Yet Recruiting	Long Term Efficacy of Faricimab Using a Treat and Extend Regimen for Type 3 Macular Neovascularization NCT07187804	Kim's Eye Hospital	Phase 4
Not Yet Recruiting	Research on a New Intelligent Mobile Screening and Diagnosis Pattern for Ocular Diseases NCT07003165	Zhongshan Ophthalmic Center, Sun Yat-sen University	—
Recruiting	Microcurrent Stimulation Therapy for Intermediate to Advanced Nonexudative Age-related Macular Degeneration NCT06662162	i-Lumen Scientific AUS PTY LTD	N/A
Recruiting	Switching to Aflibercept 8mg in Patients Showing Limited Response to Previous Treatment NCT06683950	Kim's Eye Hospital	Phase 4
Not Yet Recruiting	Prediction Model of Treatment Efficacy for Age-related Macular Degeneration Based on Multi-source Imaging Moda NCT06583109	Beijing Hospital	—
Active Not Recruiting	ReNEW:Phase 3 Study of Efficacy, Safety & Pharmacokinetics of Subcutaneous Injections of Elamipretide in Subje NCT06373731	Stealth BioTherapeutics Inc.	Phase 3
Active Not Recruiting	Can the Risk for AMD be Modulated? NCT05735730	Association for Innovation and Biomedical Research on Light and Image	N/A
Completed	Comparison of Intravitreal Anti-VEGF Treatment Burden in Different Retinal Diseases NCT07514559	Hospital Hietzing	—
Unknown	Efficacy, Safety, pharmacokinetiсs, Immunogenicity of GNR-067 and Lucentis® NCT04667039	AO GENERIUM	Phase 3
Terminated	PIIR Study: Comparison of Genetic Tests for Age-Related Macular Degeneration NCT02779686	University of Missouri-Columbia	—
Completed	EFFECT:Eccentric Fixation From Enhanced Clinical Training NCT01499628	Moorfields Eye Hospital NHS Foundation Trust	N/A
Completed	Study of Ranibizumab Administered in Conjunction With Photodynamic Therapy With Verteporfin in Patients With S NCT00288561	Novartis	Phase 2